Matching articles for "Weltruza"

Weltruza — A Once-Monthly Subcutaneous Formulation of Olanzapine

   
The Medical Letter on Drugs and Therapeutics • November 23, 2026;  (Issue 1768)
Weltruza (Teva), a once-monthly subcutaneous (SC) formulation of the second-generation antipsychotic drug olanzapine, has been approved by the FDA for treatment of schizophrenia in adults. A long-acting...
Weltruza (Teva), a once-monthly subcutaneous (SC) formulation of the second-generation antipsychotic drug olanzapine, has been approved by the FDA for treatment of schizophrenia in adults. A long-acting intramuscular (IM) formulation of olanzapine (Zyprexa Relprevv) is approved for the same indication.
Med Lett Drugs Ther. 2026 Nov 23;68(1768):187-8 | Show Full IntroductionHide Full Introduction